Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?

Area of Science:

• Nephrology
• Cardiology
• Public Health

Background:

• Chronic kidney disease (CKD) is a significant risk factor for cardiovascular disease (CVD).
• Stage 3 CKD, defined by an estimated glomerular filtration rate (eGFR) of 30-59 ml/min/1.73 m2, requires focused management.
• International guidelines recognize CKD patients as a high-risk population for CVD.

Discussion:

• Lifestyle modifications and pharmacotherapy are crucial for managing CVD risk in CKD patients.
• These interventions may stabilize or even improve renal function in stage 3 CKD.
• Addressing both CVD risk and CKD progression is paramount.

Key Insights:

• CKD is strongly linked to increased CVD event risk.
• Stage 3 CKD management strategies should target both cardiovascular and renal health.
• Proactive treatment can alter the trajectory of CKD and CVD.

Outlook:

• Further research into optimal therapeutic strategies for co-managed CKD and CVD is warranted.
• Implementation of guideline-recommended interventions can improve patient outcomes.
• Long-term studies are needed to fully assess the impact of interventions on renal and cardiovascular health.